Author

Jonas F Ludvigsson

Risk factors of small bowel tumours in CeD
Risk factors of small bowel tumours in CeD

Jonas F Ludvigsson

REAL-WORLD OUTCOMES OF TRANSITIONING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB TREATMENT: A NATIONWIDE COHORT BASED ON THE SWEDISH INFLAMMATORY BOWEL DISEASE QUALITY REGISTER
REAL-WORLD OUTCOMES OF TRANSITIONING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB TREATMENT: A NATIONWIDE COHORT BASED ON THE SWEDISH INFLAMMATORY BOWEL DISEASE QUALITY REGISTER

Jonas F Ludvigsson  et al.

ASSOCIATION BETWEEN INFLAMMATORY BOWEL DISEASE AND SPONDYLOARTHROPATHIES: FINDINGS FROM A NATIONWIDE STUDY IN SWEDEN
ASSOCIATION BETWEEN INFLAMMATORY BOWEL DISEASE AND SPONDYLOARTHROPATHIES: FINDINGS FROM A NATIONWIDE STUDY IN SWEDEN

Jonas F Ludvigsson  et al.

THE RISK OF SERIOUS INFECTIONS BEFORE AND AFTER ANTI-TNF THERAPY IN INFLAMMATORY BOWEL DISEASE – A RETROSPECTIVE COHORT STUDY
THE RISK OF SERIOUS INFECTIONS BEFORE AND AFTER ANTI-TNF THERAPY IN INFLAMMATORY BOWEL DISEASE – A RETROSPECTIVE COHORT STUDY

Jonas F Ludvigsson  et al.

MICROSCOPIC COLITIS NO MORE: HLA ASSOCIATION DISCRIMINATES COLLAGENOUS FROM LYMPHOCYTIC COLITIS
MICROSCOPIC COLITIS NO MORE: HLA ASSOCIATION DISCRIMINATES COLLAGENOUS FROM LYMPHOCYTIC COLITIS

Jonas F Ludvigsson  et al.

Item 1 - 5 / 5
1